We are engaged in the development of next generation therapeutics in osteoporosis. We have developed a regenerative medicine approach for fragility fractures,  improving implant anchorage leading to less fixation failures, re-operations, reduced societal costs and better quality of life.

The concept has been tested and proven in-vitro, in pre-clinical in-vivo studies, and in osteoporotic human bone explants, and is currently undergoing a feasibility study.